| This week's sponsor is Premier Research. | | | Discovering the Great Potential of Immuno-Oncology Drugs
Immuno-modulating agents have been around a long time, but for limited uses. New immuno-oncology pathways promise big advances against a wider range of cancers. Register now for our May 23 webinar. Premier Research. It's what we do. Best. |
Featured Story | Tuesday, May 16, 2017 Editas Medicine has delayed the target date for filing an IND for its lead candidate. The setback to the Allergan-partnered CRISPR program stems from delays at a third-party manufacturer working on Leber congenital amaurosis treatment LCA10. |
|
|
| This week's sponsor is Medpace. | | | |
Top Stories | Tuesday, May 16, 2017 New FDA Commissioner Scott Gottlieb delivered his first address to agency workers yesterday, and tackling high drug prices featured prominently in the speech. |
|
|
| Tuesday, May 16, 2017 Synlogic has landed a Nasdaq listing and an $82 million cash pile by simultaneously pulling off a reverse merger with Mirna Therapeutics and a Series C round. The activity tees up the Jose Carlos Gutierrez-Ramos, Ph.D.-helmed synthetic biology startup to push its lead candidate into the clinic in the coming months. |
|
|
| Tuesday, May 16, 2017 Vifor Pharma has struck a deal to sell Akebia Therapeutics’ phase 3 oral anemia drug vadadustat through its network of U.S. dialysis centers. The deal brings together two prolific dealmakers that have both spent the past two years wheeling and dealing to improve their prospects. |
|
|
| Tuesday, May 16, 2017 AstraZeneca's European pharma VP is reported to be on "gardening leave" after his employer sues for breaching his employment contract. |
|
|
| Monday, May 15, 2017 Metformin has been helping patients with Type 2 diabetes control their blood sugar for more than two decades, but now researchers led by McGill University are investigating a new use for the drug: to treat fragile X syndrome, which causes some forms of autism. |
|
|
| Tuesday, May 16, 2017 Branded drugmakers weren't the only ones working through a tumultuous 2016. Generics companies faced pricing pressure, too. And while branded companies suffer pricing pain on costly cutting-edge therapies, generics outfits feel the pinch with already-thin margins, making pressure all the more agonizing. |
|
|
| This week's sponsor is Cmed Research. | | | |
| | | RNA player Silence Therapeutics alleged, by pointing without naming names, that other companies' late-phase candidates infringe its patents. Statement Argenx upped the number of shares it plans to sell in its IPO by 39%. Release Vertex entered into a multitarget genetic disease collaboration with X-Chem. Statement | |
|
Resources Presented By: Covance The ICH GCP E6 guideline has been revised to address the complexities associated with today’s clinical trials, and this concise white paper will help you understand the recent guideline changes. Learn how use of risk-based monitoring can help you comply with the guidelines and achieve efficiency in clinical trial design, implementation and reporting. Sponsored By: Veeva To thrive in a fiercely competitive market, life sciences companies need to set themselves apart by designing and executing the best trial and successfully deliver drugs to market first. Learn how a modern EDC can help. Sponsored By Reprints Desk Puzzled by Scientific Literature Access? Here is your guide for navigating knowledge management’s twists and turns! If yours is a small- or medium-sized biopharma business, we can help you putting the pieces together. Learn the secrets of top knowledge management experts who will show you how to search, discover, acquire and manage knowledge in new ways. Presented By: Covance The recent evolution of immunotherapies and their potential applications have greatly impacted patients’ options for effective oncology treatments. These advances have been powered in part by the use of biomarkers, companion diagnostics (CDx) and complementary diagnostics. Read the white paper. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. MIXiii-BIOMED 2017 May 23-25, 2017 | Tel Aviv, Israel 8th Transparency and Aggregate Spend West May 23-24, 2017 | San Diego, CA Life Sciences Event of the Year! DIA 2017 Global Annual Meeting 2017 BIO International Convention: The Largest Global Biotech Partnering Event of the Year June 19-22 | San Diego, CA Rational Combinations 360° in Immuno-Oncology June 28-29, 2017 | New York, NY Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA FierceBiotech Executive Breakfast- Tackling the Drug Price Problem: A Town Hall Debate June 21, 2017 | San Diego, CA FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA |
